Ghazala O Keefe, MD
Ophthalmology · Atlanta, GANPI 1093954000
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,250 of the $3,315 with a category attached, or 67.9%. Eyepoint US, Inc. accounts for 69.8% of it on its own, with 1 other manufacturer making up the rest.
Across 3 payments — averaging $1105.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyepoint US, Inc.$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
Across 5 payments — averaging $8300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$25K
- Janssen Research & Development, LLC$12K
- Eyepoint US, Inc.$5K
What the payments were for
- Consulting fees$2,25068%
- Speaking & faculty fees$1,00030%
- Food & beverage$652%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyepoint US, Inc. | 2 | $2,315 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $1,000 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,315 in reported general payments places this provider in the 65th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Difluprednate | 26 | $5,414 |
| Prednisolone Acetate | 88 | $4,808 |
| Methazolamide | 19 | $3,048 |
| ValacyclovirValacyclovir Hcl | 22 | $1,376 |
| Ketorolac Tromethamine | 27 | $827 |
| Brimonidine Tartrate | 38 | $672 |
| Prednisone | 36 | $303 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 29 | $285 |
| Latanoprost | 26 | $281 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Atlanta
- Gagan SawhneyAtlanta$582K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Evan SchoenbergAtlanta$130K
- Robert StultingAtlanta$85K
- David SackelAtlanta$82K
- Atul SharmaAtlanta$77K
- Daniel MartinAtlanta$55K
- Douglas DayAtlanta$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.